A
Andrea Wang
Researcher at Amgen
Publications - 47
Citations - 7897
Andrea Wang is an academic researcher from Amgen. The author has contributed to research in topics: Denosumab & Osteoporosis. The author has an hindex of 25, co-authored 47 publications receiving 6863 citations. Previous affiliations of Andrea Wang include Cornell University & Georgetown University.
Papers
More filters
Journal ArticleDOI
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings,Javier San Martin,Michael R. McClung,Ethel S. Siris,Richard Eastell,Ian R. Reid,Pierre D. Delmas,Holly B. Zoog,M. Austin,Andrea Wang,Stepan Kutilek,Silvano Adami,Jose R. Zanchetta,Cesar Libanati,Suresh Siddhanti,Claus Christiansen +15 more
TL;DR: Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis.
Journal ArticleDOI
Etanercept as monotherapy in patients with psoriasis
Craig L. Leonardi,Jerold Powers,Robert Matheson,Bernard S. Goffe,Ralph Zitnik,Andrea Wang,Alice B. Gottlieb +6 more
TL;DR: The treatment of psoriasis with etanercept led to a significant reduction in the severity of disease over a period of 24 weeks, paralleled by improvements in global assessments by physicians and the patients and in quality-of-life measures.
Journal ArticleDOI
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
Stephen K. Tyring,Alice B. Gottlieb,Kim A. Papp,Kenneth B. Gordon,Craig L. Leonardi,Andrea Wang,Deepa Lalla,Michael Woolley,Angelika Jahreis,Ralph Zitnik,David Cella,Ranga Krishnan +11 more
TL;DR: Improvements in fatigue were correlated with decreasing joint pain, whereas improvements in symptoms of depression were less correlated with objective measures of skin clearance or joint pain.
Journal ArticleDOI
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Henry G. Bone,Rachel B. Wagman,Maria Luisa Brandi,Jacques P. Brown,Roland Chapurlat,Steven R. Cummings,Edward Czerwiński,Astrid Fahrleitner-Pammer,David L. Kendler,Kurt Lippuner,Jean-Yves Reginster,Christian Roux,Jorge Malouf,Michelle N. Bradley,Nadia Daizadeh,Andrea Wang,P. Dakin,Nicola Pannacciulli,David W. Dempster,S. Papapoulos +19 more
TL;DR: The yearly exposure-adjusted participant incidence of adverse events for all individuals receiving denosumab decreased from 165·3 to 95·9 per 100 participant-years over the course of 10 years, and serious adverse event rates were generally stable over time.
Journal ArticleDOI
Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD
E. Michael Lewiecki,Paul D. Miller,Michael R. McClung,Stanley Cohen,Michael A. Bolognese,Yu Liu,Andrea Wang,S. Siddhanti,Lorraine A. Fitzpatrick +8 more
TL;DR: Subcutaneous denosumab given every 3 or 6 mo was well tolerated, increased BMD, and decreased bone resorption markers for up to 24 mo, which is warranted in the treatment of low BMD in postmenopausal women.